Skip to main content
. 2022 Jul 11;14(14):3367. doi: 10.3390/cancers14143367

Figure 1.

Figure 1

Clinical outcome of Atezo/Bev treatment in 85 u-HCC patients. (A) The best response to Atezo/Bev was assessed by mRECIST. (B,C) Kaplan–Meier curves of progression-free survival (PFS) (B) and overall survival (OS) (C). u-HCC, unresectable hepatocellular carcinoma; Atezo/Bev, Atezolizumab and bevacizumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease, NE, not evaluated; DCR, disease control rate; ORR, overall response rate.